HeyJaredJules Adam
- Indexed articles, last 90 days
- 8
- Latest publication
- Aug 3, 2026
- Outlet visibility, for Labiotech.eu
- Top 5M sites
- Earliest in this view
- Jul 3, 2026
Latest articles
10 biotechs in Japan to watch in 2026 (opens the original)
Read excerpt
While Japan historically lacked foreign investment, the field is becoming more dynamic. Discover ten essential biotech companies in Japan. The post 10 biotechs in Japan to watch in 2026 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and
Merck after Keytruda: what the pipeline looks like (opens the original)
Read excerpt
Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry. The post Merck after Keytruda: what the pipeline looks like appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s (opens the original)
Read excerpt
Today we welcome Gene Mack, President and CEO of Gain Therapeutics. Their lead candidate is advancing toward Phase 2 as a potential first-in-class disease-modifying therapy for Parkinson’s disease The post Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s auth
This nonprofit is building the ecosystem to cure epidermolysis bullosa (opens the original)
Read excerpt
Our guest today is Martin Steiner, Managing Director of DEBRA Research, a non-profit organization with a mission: to make epidermolysis bullosa curable The post This nonprofit is building the ecosystem to cure epidermolysis bullosa appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may b
Is an HIV cure possible? The future of HIV therapy (opens the original)
Read excerpt
Delve into the field of HIV treatment development. Since the virus was discovered, treatments have improved, but are we close to a cure? The post Is an HIV cure possible? The future of HIV therapy appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labio
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Labiotech.eu, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.